Vagitocin (oxytocin topical) / Peptonic Medical  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vagitocin (oxytocin topical) / Peptonic Medical
NCT02497547: An Efficacy Study of Vagitocin in Postmenopausal Women With Symptoms of Vaginal Atrophy

Completed
2b
227
Europe
Oxytocin, Vagitocin, Placebo
PepTonic Medical AB, A+ Science AB
Atrophy
07/15
07/15
NCT04629885 / 2016-000158-36: Study to Evaluate Efficacy of Vagitocin in Postmenopausal Women With Vulvovaginal Atrophy Symptoms

Completed
2b
202
Europe
Oxytocin 400 IU vaginal gel, Vagitocin, Placebo, Placebo (for Vagitocin)
PepTonic Medical AB
Vulvovaginal Atrophy
05/17
05/17
NCT01432470 / 2009-016613-22: Study of Oxytocin to Treat Vaginal Atrophy in Postmenopausal Women

Completed
2
74
Europe
Oxytocin, Placebo
PepTonic Medical AB
Postmenopause, Vaginal Atrophy
06/11
06/11
OXYPEP002, NCT01987804 / 2011-005465-20: Dose-relationship of Vaginally Administrated Oxytocin in Postmenopausal Women

Completed
2
64
Europe
Oxytocin 100 i.u., Vagoticin, Oxytocin 400 i.u., Placebo
PepTonic Medical AB, Pharma Consulting Group AB
Vaginal Atrophy
12/12
01/13
NCT01975129 / 2013-002690-22: A Pharmacokinetic Study of Vaginally and Intravenously Administered Oxytocin

Completed
2
12
Europe
Vagitocin, Oxytocin gel 400 International Units
PepTonic Medical AB
Vaginal Atrophy
02/14
02/14

Download Options